Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

SER-109 has FDA Breakthrough Therapy designation, which provides the potential for priority review of the BLA.